Giulio M Pasinetti, MD, PhD
- Research Scientist
Research Topics:Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Diabetes, Genomics, Memory, Obesity, Parkinson's Disease
Dr. Giulio Maria Pasinetti, The Saunders Family Chair and Professor of Neurology, received an M.D. from the Milan University School of Medicine and a Ph.D. from the University of Milan. He is currently the Program Director of the NIH funded Mount Sinai Center for Molecular Integrative Neuroresilience and the Chief of the Brain Institute Center of Excellence for Novel Approaches to Neurodiagnostics and Neurotherapeutics. He is also a Professor of Psychiatry, of Neuroscience, and of Geriatrics and Adult Development. Dr. Pasinetti is the recipient of several academic awards including the prestigious Zenith and Temple awards from the Alzheimer's Association. Most recently, Dr. Pasinetti was awarded ''The Faculty Council Award'' for academic excellence at Mount Sinai School of Medicine and "The Charles Dana Alliance for Brain Research Award" from Dana Foundation, recognizing productivity and worldwide leadership in his field of expertise, which further emphasizes his standing as an academic role model.
Multi-Disciplinary Training AreaNeuroscience [NEU]
MD, University of Milan Medical School
PhD, University of Milan
Turken Family fellowship from Alzheimer's Association
Faculty Council Award for Academic Excellence
Nathan W. & Margaret T. Shock Aging Research Foundation Award of the Gerontology Society of America
Foundation Queen Sofia of Spain Research Center award on Alzheimer's Disease
Temple Foundation Discovery Award from Alzheimer's Association
Nathan Shock New Investigator Award of the Gerontology Society of America
Dana Alliance for Brain Initiatives Award
Zenith Award from Alzheimer's Association
Dr. Pasinetti is the Director of Basic and Biomedical Research and Training at the Geriatric Education and Clinical Research at the James J Peters Veterans Affairs, Bronx where he developed programs to train health science students in the field of geriatrics in order to help increase the basic knowledge of aging, transmit this knowledge to health care providers, and improve the quality of care delivered to elders. Collectively, the work of Dr. Pasinetti directly develops research to improve the care and treatment for the aging Veteran population while at the same time training many of the healthcare professionals who will provide that care for years to come.
The primary research goals of Dr. Pasinetti's lab is to investigate the biological processes which occur when, during aging, subjects with normal cognitive function convert into the very earliest stages of Alzheimer's disease and then to frank dementia. More recently, Dr. Pasinetti has conducted genome wide association studies to clarify the molecular mechanisms in subjects with type 2 diabetes that might be predisposed to the onset of Alzheimer’s disease.
Look AHEAD (Action for Health in Diabetes)
Dr. Pasinetti's laboratory is currently focused on building a model based on genetic and environmental information to predict cognitive decline in overweight and obese individuals with type 2 diabetes. Ultimately, the study will allow the prediction of the long-term effects of intensive weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study. The lab will use independent study cohorts from other Biobanks to validate their comprehensive model. These studies will be critical for developing and redirecting efforts for potential therapeutic intervention in a subpopulation of type 2 diabetic subjects who are at high risk for cognitive deterioration.
Drug discovery and repurposing
As Chief of the Brain Institute Center of Excellence for Novel Approaches to Neurodiagnostics and Neurotherapeutics, Dr. Pasinetti has developed novel drug discovery programs for Alzheimer’s disease. Dr. Pasinetti is leading a primary translational Center to determine whether interventions which appear to work in the preclinical animal model of the disease also show promise in treating patients who have the disease. Dr. Pasinetti is utilizing innovative, drug discovery, genomic and proteomic technologies, which offer the promise to shed light on largely unseen details of disease causality, onset, and progression. Through the approach of “repurposing currently used drugs for other indications” Dr. Pasinetti is currently identifying new therapies that will provide clinical benefits
As Director of the NIH funded Botanical Center in Neuroresilience, Dr Pasinetti is investigating certain dietary supplements, in particular polyphenols, against stressful events and clarifying the role of the microbiome at the genomic level in the promotion of cognitive and psychological health. Dr. Pasinetti received a competitive award for $10 million for five years to conduct research under his leadership in the Department of Neurology. The Center will support three major projects which will be conducted through interdisciplinary collaborative efforts from the Department of Neuroscience, Department of Neurology, Department of Genetics and Genomic Sciences, and the Friedman Brain Institute. The Center research will lead to safe and efficacious treatments of dietary botanical supplements to promote resilience in response to psychological and cognitive stress.
Pasinetti GM. Towards prevention and therapy of Alzheimer's disease. Molecular Aspects of Medicine; 43-44.
Hao K, Di Narzo AF, Ho L, Luo W, Li S, Chen R, Li T, Dubner L, Pasinetti GM. Shared genetic etiology underlying Alzheimer's disease and type 2 diabetes. Molecular Aspects of Medicine 2015 Jun;.
Wang D, Ho L, Faith J, Ono K, Janle EM, Lachcik PJ, Cooper BR, Jannasch AH, D'Arcy BR, Williams BA, Ferruzzi MG, Levine S, Zhao W, Dubner L, Pasinetti GM. Role of intestinal microbiota in the generation of polyphenol-derived phenolic acid mediated attenuation of Alzheimer's disease β-amyloid oligomerization. Molecular nutrition & food research 2015 Jun; 59(6).
Vidaurre OG, Haines JD, Katz Sand I, Adula KP, Huynh JL, McGraw CA, Zhang F, Varghese M, Sotirchos E, Bhargava P, Bandaru VV, Pasinetti G, Zhang W, Inglese M, Calabresi PA, Wu G, Miller AE, Haughey NJ, Lublin FD, Casaccia P. Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain 2014 Aug; 137(Pt 8).
Wang J, Bi W, Cheng A, Freire D, Vempati P, Zhao W, Gong B, Janle EM, Chen TY, Ferruzzi MG, Schmeidler J, Ho L, Pasinetti GM. Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications. Frontiers in aging neuroscience 2014; 6.
Wang J, Gong B, Zhao W, Tang C, Varghese M, Nguyen T, Bi W, Bilski A, Begum S, Vempati P, Knable L, Ho L, Pasinetti GM. Epigenetic mechanisms linking diabetes and synaptic impairments. Diabetes 2014 Feb; 63(2).
Wang J, Ferruzzi MG, Ho L, Blount J, Janle E, Gong B, Pan Y, Raftery D, Arrieta-Cruz I, Sharma V, Cooper B, Lobo J, Simon JE, Zhang C, Cheng A, Qian X, Ono K, Teplow D, Pavlides C, Dixon R, Pasinetti GM. Brain Targeting Proanthocyanidin Metabolites for Alzheimer’s Disease Treatment . Journal of Neuroscience 2012;.
Dixon RA, Pasinetti GM. Flavonoids and isoflavonoids: from plant biology to agriculture and neuroscience. Plant physiology 2010 Oct; 154(2).
Qin W, Haroutunian V, Katsel P, Cardozo CP, Ho L, Buxbaum JD, Pasinetti GM. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. JAMA Neurology 2009 Mar; 66(3).
Pasinetti GM. Anti-inflammator drugs fall short in Alzheimer's disease. Nature Medicine 2008; 14(9).
Wang J, Ho L, Zhao W, Ono K, Rosensweig C, Chen L, Humala N, Teplow DB, Pasinetti GM. Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. The Journal of Neuroscience 2008 Jun; 28(25).
Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, Yuan X, Brown RH, Cudkowicz ME, Newhall K, Peskind E, Marcus S, Ho L. Identification of potential CSF biomarkers in ALS. Neurology 2006 Apr; 66(8).